Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: Report of three cases

Clinical Journal of Gastroenterology

Volumn 5, Issue 6, 2012, Pages 407-412

  Takeda, Haruhiko ^a   Nishikawa, Hiroki ^a   Iguchi, Eriko ^a   Matsuda, Fumihiro ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Acute interstitial pneumonia; Adverse event; Hepatocellular carcinoma; Lung injury; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLINESTERASE; CREATINE KINASE; DECARBOXYPROTHROMBIN; HYDROCORTISONE; IMMUNOGLOBULIN E; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; SERUM ALBUMIN; SORAFENIB;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BRONCHOSCOPY; CASE REPORT; CHILD PUGH SCORE; CHOLINESTERASE BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; HUMAN; HYPERTENSION; HYPOXEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFORMATION TEST; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PULSE OXIMETRY; RESPIRATORY FUNCTION; SKIN MANIFESTATION; THORAX RADIOGRAPHY; TREATMENT DURATION; VITAL CAPACITY;

EID: 84876290448     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-012-0339-9     Document Type: Article

References (20)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
2. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-300.
3. Miyagawa N, Akaza H. Sorafenib (Nexavar). Gan To Kagaku Ryoho. 2009;36:1029-33.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
5. Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancer. 2012;4:165-83.
6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
7. Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Yoon HI, et al. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver. 2010;4:543-6.
8. Ide S, Soda H, Hakariya T, Takemoto S, Ishimoto H, Tomari T, et al. Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event. Lung Cancer. 2010;67:248-50.
9. Bayer HealthCare Japan. Safety information for Nexabar™ 200 mg tablets. December 2008 (in Japanese).
10. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, Inoue Y, Sakai F et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol. 2012;30.
11. Mueller-Mang C, Grosse C, Schmid K, Stiebellehner L, Bankier AA. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics. 2007;27:595-615.
12. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303-6.
13. Gemma A. Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med Sch. 2009;76:4-8.
14. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.
15. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39.
16. Papaopannou AI, Konstikas K, Kollia P, Gourgoulianis KI. Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res. 2006;7:128.
17. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-77.
18. Mura M, Santos CC, Stewart D, Liu M. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol. 2004;97:1605-17.
19. Richter AG, Maughan EO, Perkins GD, Nathami N, Thickett DR. VEGF levels in pulmonary fibrosis. Thorax. 2005;60:171-3.
20. Sobin LH, Gospodarowitz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. UICC InternationalUnion Against Cancer;2009.